anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Cervical dystonia (CD) is a movement disorder characterized by involuntary muscle contractions causing sustained twisting movements and abnormal postures of the neck and head. Assumed affected neuronal regions are the cortico-striatal-thalamo-cortical circuits, which are also involved in cognitive functioning. Indeed, impairments in different cognitive domains have been found in CD patients. However, to date studies have only investigated a limited range of cognitive functions within the same sample. In particular, social cognition (SC) is often missing from study designs. Hence, we aimed to evaluate a broad range of cognitive functions including SC in CD patients.
METHOD: In the present study 20 idiopathic CD patients and 40 age-, gender-, and IQ-matched healthy controls (HCs) were assessed with tests for non-SC (verbal memory, psychomotor speed, and executive functions) as well as for SC (emotion recognition, Theory of Mind (ToM), and empathy).
RESULTS: CD patients scored on average significantly lower than HC on tests for non-SC, but did not show impairments on any of the tests for SC.
CONCLUSIONS: The current study showed impairments in non-SC in CD, but intact social cognitive functions. These results underline the importance of recognizing non-motor symptoms in idiopathic CD patients, but emphasize a focus on identifying strengths and weaknesses in cognitive functioning as these influence daily life activities.
The invention relates to herbal disinfectant. The herbal disinfectant is characterized by comprising the following components, 2 parts of mint leaf extract, 2 parts of propylene glycol, 5 parts of triclosan, 1 part of borneol, 2 parts of folium artemisiae argyi, 3 parts of gallnut, 10 parts of lauric acid fatty acid, 12 parts of glyceride, 2 parts of Tea Tree Oil, 3 parts of propolis, 3 parts of aloe extract, and 2 parts of licorice extract. With the addition of chlorine dioxide, triclosan and other active ingredients, the disinfectant containing the herbal components is prepared into an efficient, harmfulless, quick and spectral bactericide which is high in bactericidal ability and free of pollution. The disinfectant is prepared from pure extracting solutions, is good in bactericidal effect, and is safe, efficient, green and environment-friendly. The disinfectant is completely prepared from a natural herb preparation, has a good bactericidal effect, realizes broad-spectrum bactericidal, and is specifically suitable for various disinfecting and sterilizing related to life. The mint leaf extract, borneol, folium artemisiae argyi and gallnut and other components are added, which can protect the skin, continuously act and bring a pleasant fresh scent.
The first choice for the treatment of PPGL is surgery. PPGL can be cured by complete resection of the lesion. However, some PPGLs could not be performed R0 resection due to the large tumor size and close relationship with surrounding tissues (blood vessels, kidneys, pancreas, liver, etc.). In this case, in order to achieve R0 resection, they need to undergo expand the scope of surgery, such as simultaneous resection of vital organs,and with extreamly high risks.There is no treatment option for those locally advanced or unresectable PPGLpatients currently. Temozolomide (TMZ), an oral alkylation chemotherapeutic agent, has been used in recent years and shown to have beneficial effects on metastatic PPGL with few side effects. TMZ has been recommended in National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2022 for treating metastatic PPGL patients. This prospective, single arm, phase II study is designed to evaluate the efficacy of neoadjuvant therapy with TMZ in locally advanced,or unresectable PPGL patients or patients with severe catecholamine cardiomyopathy who are intolerance of operation.TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days. Imaging examinations will be conducted after3 courses to re-evaluate the surgical possibility and surgery risks. If the patient's tumor shrinks after 3 courses but is still unresectable, the patients will continue TMZ therapy for another 3 courses.
PURPOSE:To obtain a new triterpene sulfonate derivative, capable of antagonizing the binding of endothelin to an endothelin receptor and useful for preventing and treating diseases caused by the action of the endothelin, e.g. the elevation of blood pressure, ischemic cardiopathy or cerebral circulatory disorder. CONSTITUTION:This compound is expressed by formula I (R<1> is H or metabolic ester residue) or its pharmaceutically permissible salt, e.g. a compound expressed by formula II. The compound expressed by formula I is obtained by using an aldehyde corresponding to a compound expressed by formula III as a starting substance, condensing the aldehyde with an aldehyde in the presence of cesium carbonate or lithium carbonate and an amine such as triethylamine according to the Horner-Emmons method, then deprotecting the prepared compound and sulfonating the obtained amine. This compound expressed by formula I is effective in preventing and treating diseases such as nephropathy, circulation failure in various organs and asthma.
Provided is an application of a histone deubiquitinase in the preparation of drugs for preventing aging and treating aging-related diseases, relating to the technical field of biomedicines. The nucleotide sequence of the histone H2A deubiquitinase MYSM1 is as shown in SEQ ID NO. 1. Upon verification, the lack of MYSM1 proteins results in significant aging and induces aging-related diseases in a mouse. MYSM1 promotes DNA damage repair, impedes cellular senescence, and inhibits chronic inflammations. An adeno-associated virus expressing murine MYSM1 is used as a result of gene therapy to prove that MYSM1 can significantly prolong the lifespan of a mouse, reduce the progression and number of senescent cells, improve normal functions of tissue and organs, and reduce the occurrence and development of aging-related diseases, thus proving that MYSM1 has good prospects for application in delaying aging and treating aging-related diseases.
Known synthetic materials have limitations and disadvantages such as a limited range of physical and biochemical properties. The present disclosure teaches a microbially-derived implantable cellulose, wherein the material is capable of in vivo implantation. The method for producing the same is also described. The method may include: treating the material to render the cellulose non-pyrogenic; dehydrating the material in a continuous manner by applying a water-miscible organic solvent; and subsequently removing the solvent. The material can be used as a tissue substitute, bulking agent and a surgical mesh. The microbially-derived implantable cellulose may also be capable of in vivo implantation, and may have desirable mechanical properties such as tensile strength, elongation and sutureability. The microbially-derived cellulose may also be non-pyrogenic and biocompatible and may be capable of being sterilized.
Patients receive cold basiliximab IV, 111In-DOTA-anti-CD25 basiliximab IV, and 90Y-DOTA-anti-CD25 basiliximab IV on day -15. Patients also receive palifermin IV on days -11 to -9, fludarabine phosphate IV on days -4 to -2, melphalan IV on day -2, and undergo TMLI on days -8 to -5 in the absence of disease progression or unacceptable toxicity. Patients then undergo AHSCT on day 0.
Participants in this arm are educated using the DALE strategy, developed in 2012 by researchers at the University of Guadalajara. Similar to the RAPIDO strategy, DALE adapts the FAST mnemonic for the Spanish-speaking population, promoting quick recognition and response to cerebrovascular symptoms.
Chronic lymphocytic leukemia (CLL) is a monoclonal hematopoietic disorder characterized by a progressive expansions of lymphocytes of B-cell lineage. These small, mature-appearing lymphocytes accumulate in the blood, bone marrow, lymph nodes, and spleen. CLL is a common leukemia in the wester world and accounts for 25% to 30% of adult leukemias. CD19,an integral membrane protein, is expressed by pro-B cells and functions as a co-stimulatory molecule that regulates mature B-cell activation and enhances B-cell proliferation. MDX-1342, a fully human monoclonal antibody, has demonstrated to specifically bind to human CD19 antigen with high affinity. Therefore, it is theorized that MDX-1342 will block activation of B cell stimulation, decreasing the number of cancerous B cell clones.
When adult patients on hemodialysis are given the recommended daily dose of 500 mg of Ertapenem for injection within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the hemodialysis session. If Ertapenem for injection is given at least 6 hours prior to hemodialysis, no supplementary dose is needed. There are no data in patients undergoing peritoneal dialysis or hemofiltration. There are no data in pediatric patients on hemodialysis.

When only the serum creatinine is available, the following formula[1] may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function.

1 Cockcroft and Gault equation: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976.
This is a Phase 2, controlled study of BIO-11006 peptide given in addition to Gemcitabine and Docetaxel (GemTax) in the treatment of patients with advanced osteosarcoma or Ewing's sarcoma with lung metastases. Patients will receive BIO-11006 in addition to GemTax chemotherapy, which is a current institutional treatment option for recurrent Osteosarcoma and Ewings's Sarcoma. The BIO-11006 inhalation solution will be given by mouth inhalation twice daily. BIO-11006 will be given during the first three cycles and then will be stopped. Patients will continue on GemTax for up to 6 additional cycles and will be clinically assessed before every cycle and have standard-of-care imaging assessments after cycle 3, 6 and 9. If the patient shows lung progression (either clinical or on imaging) at any point after cycle 4 has been given, but had shown at least a partial response during the tumor assessment after cycle 3, BIO-11006 may be re-started at the discretion of the investigator and continued for the duration of the GemTax treatment. Subjects will be followed for disease status during routine clinical follow-ups for 9 months post the end of study treatment. The trial will be conducted at a single site.
This study will improve standardization for the delivery of transcutaneous tibial nerve stimulation as a treatment modality for overactive bladder in post-menopausal women and contribute to lower cost care options within the home environment. This is a prospective randomized control trial where the participants' baseline conditions will be utilized for comparison with post-treatment. The independent variable is transcutaneous tibial nerve stimulation. The dependent variables are urinary frequency and urinary continence episodes based on three-day bladder diary, OAB-V8, Overactive Bladder Symptom Severity Score (OABSS), Activities-specific Balance Confidence Scale (ABC-16), Geriatric Self-efficacy Index for Urinary Incontinence (GSE-UI), and the Timed-Up and Go test (TUGT). Additional pre- and post- test variables that will be considered are spatiotemporal measurements of gait with both full and empty bladder conditions.

At the first session at the School of Allied Health Professions following screening and consent, participants will complete the OAB-SS, ABC-16, and the GSE-UI. Participants will be asked to start drinking water at the start of the first session. Once the participant notes a strong desire to void that is difficult to defer based on the urgency severity scale (USS), the participant will walk along the GaitRITE pathway to the restroom. Participant will void into a urine specimen collector and bladder volume will be recorded, but urine will not be retained. The participant will then walk back over the electronic pathway to collect empty bladder condition gait. Participant will then complete the TUGT. Following this testing, participants will be instructed in home use of the transcutaneous tibial nerve stimulation. Participants will place one electrode 3 finger widths above the medial malleolus with the other placed below the medial malleolus with the following parameters: 10 Hertz, 200 microseconds, for 30 minutes to a strong but comfortable level that is under the motor threshold. Participants will complete these sessions either two or four times per week for 12 weeks or will receive no treatment for the 12 weeks. Participants will be given a log for home use to document their compliance with the home treatment.

Participants will follow up at the School of Allied Health Professions at the 6-week mark to complete the gait testing and Activities-specific Balance Confidence Scale and the Geriatric Self-Efficacy Index for Urinary Incontinence. Participants will be given supplies to complete an additional three-day bladder diary to bring with them for the 12-week follow-up. Following 12 weeks of transcutaneous tibial nerve stimulation, participants will return to the School of Allied Health Professions to complete the procedure described above.
Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
Hypertension is a serious threat to human health and a major global economic burden.Chronic hypertension can cause left ventricular remodeling and loss of function, eventually leading to heart failure. Ventricular remodeling in hypertensive patients is an adaptive and decompensating response to persistent elevated blood pressure and increased myocardial work load. Exploring the early changes and mechanisms of left ventricular cardiac function caused by hypertension, and to identify individuals who may develop into serious heart injury, may play a positive role in the early prevention and control of heart failure caused by hypertension.Therefore, this study intend to use two dimensional speckle tracking technology, a non-invasive method to measure left ventricular pressure-strain loop to quantitatively reflect cardiac work index , to study different hypertension patients with normal left ventricular ejection fraction (including hypertension without heart damage performance with different degree of high blood pressure, hypertension with diastolic dysfunction , hypertension with left ventricular hypertrophy ) the change of the global and local cardiac work, and the influence of aterosclerosis in the patients to myocardial work, and explore their relationship with ventricular remodeling and abnormal diastolic function.To improve the understanding of the pathophysiology of hypertension, hypertensive heart disease and heart failure, and to provide scientific support for the early prevention and control of such diseases.Now days, Echocardiography plays a central role in the evaluation of patients with cardiovascular disease. Echocardiography is widely available and allows characterization of the functional and structural of heart. Thus, assessment of left lentricular (LV) global longitudinal strain (LVGLS) and Myocardial work indexes has proven benefit for both diagnosis and risk in hypertension patients. Myocardial work indexes have four indexes to evaluate different function of lentricular. However, there is still no research investigating the the relationship between blood pressure and Myocardial work indexes in patients with different levels of blood pressure.
Patients will be instructed to check their glucose 4 times a day, every day. This is currently the standard of care.
Patients in this cohort are participating in the All4Cure platform and there has been an established intention to treat according to the clinical pathway. Additionally, the patient's primary physician will also be a participant in the All4Cure platform.
Patient underwent surgery for morbid obesity treatment between 18 to 60 years, and BMI of 40 ore more will divided in two groups, one hundred will be schedule for laparoscopic gastric plication. Our theory for this arm is that the procedure can offer the same results than the second arm with less cost and safety, reversibility included.
CHD 1L-driven cancers, including TCF transcription-driven cancers and EMT-driven cancers, are treated with CHD1L inhibitors. Small molecule inhibitors of CHDL1 that inhibit CHD1L atpase and inhibit CHD 1L-dependent TCF transcription have been identified. CHD1L inhibitors prevent binding of the TCF complex to Wnt responsive elements and promoter sites. More specifically, CHD1L inhibitors induce the reversal of EMT. CHD1L inhibitors are useful for treating various cancers, particularly CRC and m-CRC. CHD1L driven cancers include CRC, breast cancer, glioma, liver cancer, lung cancer or Gastrointestinal (GI) cancer. Provided are CHD1L inhibitors of formulae I and XX as defined herein and salts thereof and pharmaceutical compositions containing CHD1L inhibitors. Synergistic combinations of CHD1L inhibitors with other antineoplastic agents are also described.
PURPOSE: Common surgical procedures in the treatment of periprosthetic distal femur fractures (PPFF) include osteosynthesis with fixed angle locking plates (LP) and retrograde intramedullary nails (RIN). This study aimed to compare LPs to RINs with oblique fixed angle screws in terms of complications, radiographic results and functional outcome.
METHODS: 63 PPFF in 59 patients who underwent treatment in between 2009 and 2020 were included and retrospectively reviewed. The anatomic lateral and posterior distal femoral angle (aLDFA and aPDFA) were measured on post-surgery radiographs. The Fracture Mobility Score (FMS) pre- and post-surgery, information about perceived instability in the operated leg and the level of pain were obtained via a questionnaire and previous follow-up (FU) examinations in 30 patients (32 fractures).
RESULTS: The collective (median age: 78 years) included 22 fractures treated with a RIN and 41 fractures fixed with a LP. There was no difference in the occurrence of complications (median FU: 21.5 months) however the rate of implant failures requiring an implant replacement was higher in fractures treated with a LP (p = 0.043). The aPDFA was greater in fractures treated with a RIN (p = 0.04). The functional outcome was comparable between both groups (median FU: 24.5 months) with a lower outcome in the post-surgery FMS (p =  < 0.001).
CONCLUSION: Fractures treated with RIN resulted in an increased recurvation of the femur however the rate of complications and the functional outcome were comparable between the groups. The need for implant replacements following complications was higher in the LP group.
An N-phenylarylsulfonylamide compound represented by the general formula (I); an intermediate for the compound; and processes for producing these. The compound represented by the general formula (I) is bonded to a prostaglandin E2 receptor, especially an EP1 subtype receptor, to antagonize it, and has satisfactory in vivo activity because it is less affected by protein bonding. It is hence useful as an analgesic, antipyretic, remedy for frequent urination or lower urinary tract diseases, or carcinostatic substance. (I) In the formula, R1 represents COOH, etc.; R2 represents hydrogen, methyl, etc.; R3 and R4 represent a combination of methyl and methyl, etc.; R5 represents isopropyl, etc.; Ar represents thiazolyl, pyridyl, or 5-methyl-2-furyl each optionally substituted by methyl; and n is 0 or 1.
Participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days. Then Stop.
The invention discloses a maca functional beverage and a making method thereof. The maca functional beverage comprises, by weight, 50-80 parts of maca, 10-30 parts of glycyrrhiza uralensis and 5-15 parts of barbary wolfberry fruits. The method includes the steps that the maca, the glycyrrhiza uralensis and the barbary wolfberry fruits are cleaned, dried and smashed, and then mixed in proportion, so that a medicinal material mixture is obtained; purified water is added, heating, sterilizing, smashing, squeezing, filtering and residue removing are conducted, and thus a maca beverage mother solution is prepared; edible auxiliary materials are added in the maca beverage mother solution, then a proper amount of purified water is added for dilution, filtering and sterilizing are further carried out, packaging is performed after sterilization is completed, and accordingly the maca functional beverage is obtained. The maca functional beverage prepared through the method is good in mouthfeel and safe to drink. The healthcare effects of the maca, the glycyrrhiza uralensis and the barbary wolfberry fruits are fully guaranteed, and a collaborative function is achieved for increasing human body energy, delaying senescence, regulating endocrine and improving organism immunity. The maca functional beverage has the effects of supplementing nutrients, eliminating fatigue, enhancing human body vitality and the like.
The invention discloses a method and a system for constructing congenital cataract disease model pig nuclear transplantation donor cells with CRYBB2 gene mutation. The invention provides a kit, which comprises SEQ ID NO:18, CRYBB2-gRNA3 shown in SEQ ID NO:19, CRYBB2-gRNA6 and NCN protein. The NCN protein is a Cas9 protein or a fusion protein with a Cas9 protein. The application of the kit is as follows: preparing a recombinant cell; preparing a cataract model pig; preparing a cataract cell model or a cataract tissue model or a cataract organ model. The invention also provides a method for preparing recombinant cells, which comprises the following steps: and co-transfecting the CRYBB2-gRNA3, the CRYBB2-gRNA6 and the NCN protein to the pig cell to obtain a recombinant cell. The invention has great application value for researching and developing cataract drugs and disclosing pathogenesis of the cataract.
ZYFLO is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus. Therapy with ZYFLO can be continued during acute exacerbations of asthma. 

Co-administration of ZYFLO and theophylline results in, on average, an approximate doubling of serum theophylline concentrations. Theophylline dosage in these patients should be reduced and serum theophylline concentrations monitored closely (see PRECAUTIONS, Drug Interactions). 

Co-administration of ZYFLO and warfarin results in a clinically significant increase in prothrombin time (PT). Patients on oral warfarin therapy and ZYFLO should have their prothrombin times monitored closely and anticoagulant dose adjusted accordingly (see PRECAUTIONS, Drug Interactions). 

Co-administration of ZYFLO and propranolol results in doubling of propranolol AUC and consequent increased beta-blocker activity. Patients on ZYFLO and propranolol should be closely monitored and the dose of the propranolol reduced as necessary (see PRECAUTIONS, Drug Interactions).